[CH3:1][CH:2]([CH3:34])[C@H:3]([NH:11][CH2:12][C@H:13]1[CH2:18][CH2:17][CH2:16][C@@H:15]([O:19][CH2:20][C:21]2[N:22]=[C:23]([C:27]3[CH:32]=[CH:31][C:30]([CH3:33])=[CH:29][CH:28]=3)[O:24][C:25]=2[CH3:26])[CH2:14]1)[C:4]([O:6]C(C)(C)C)=[O:5].[F:35][C:36]([F:41])([F:40])[C:37]([OH:39])=[O:38]>C(O)=O>[F:35][C:36]([F:41])([F:40])[C:37]([OH:39])=[O:38].[CH3:1][CH:2]([CH3:34])[C@H:3]([NH:11][CH2:12][C@H:13]1[CH2:18][CH2:17][CH2:16][C@@H:15]([O:19][CH2:20][C:21]2[N:22]=[C:23]([C:27]3[CH:28]=[CH:29][C:30]([CH3:33])=[CH:31][CH:32]=3)[O:24][C:25]=2[CH3:26])[CH2:14]1)[C:4]([OH:6])=[O:5]40 mg of tert-butyl (S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl]amino}butyrate are dissolved in 1 ml of formic acid, and 0.5 ml of trifluoroacetic acid is added. The solution is stirred at room temperature for 18 and then concentrated completely. The residue is purified by HPLC, which gives 28.2 mg of (S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl]amino}butyric acid trifluoroacetic acid salt as a colorless solid. C24H34N2O2.C2HF3O2 (414.55); MS (ES−): 413.28 (M+−H).